Erin Quirk

2.8k total citations · 2 hit papers
42 papers, 1.8k citations indexed

About

Erin Quirk is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Erin Quirk has authored 42 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Infectious Diseases, 23 papers in Virology and 12 papers in Epidemiology. Recurrent topics in Erin Quirk's work include HIV/AIDS drug development and treatment (25 papers), HIV Research and Treatment (23 papers) and HIV/AIDS Research and Interventions (16 papers). Erin Quirk is often cited by papers focused on HIV/AIDS drug development and treatment (25 papers), HIV Research and Treatment (23 papers) and HIV/AIDS Research and Interventions (16 papers). Erin Quirk collaborates with scholars based in United States, France and United Kingdom. Erin Quirk's co-authors include Andrew Cheng, Kirsten White, Edwin DeJesus, Hal Martin, Anthony Mills, Joseph M. Custodio, Paul E. Sax, Joel E. Gallant, David A. Wohl and Xuelian Wei and has published in prestigious journals such as The Lancet, Nature Medicine and Clinical Infectious Diseases.

In The Last Decade

Erin Quirk

41 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

2017 278 citations Paul E. Sax, Anton Pozniak et al. The Lancet profile →
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

2017 257 citations Joel E. Gallant, Adriano Lazzarin et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Erin Quirk United States	19	1.6k	1.2k	605	277	181	42	1.8k
Marshall W. Fordyce United States	16	1.5k 0.9×	955 0.8×	500 0.8×	443 1.6×	179 1.0×	30	1.8k
Nicola Gianotti Italy	21	1.2k 0.8×	1.1k 0.9×	305 0.5×	306 1.1×	133 0.7×	153	1.5k
Hans-Jürgen Stellbrink Germany	10	1.4k 0.9×	1.1k 0.9×	584 1.0×	257 0.9×	115 0.6×	12	1.7k
Benoît Trottier Canada	19	1.7k 1.1×	1.5k 1.3×	374 0.6×	390 1.4×	252 1.4×	68	2.2k
Scott C. Brun United States	15	1.5k 1.0×	1.4k 1.2×	392 0.6×	183 0.7×	84 0.5×	16	1.8k
Cindy Vavro United States	15	1.4k 0.9×	1.1k 1.0×	308 0.5×	284 1.0×	173 1.0×	26	1.5k
Javier O Morales-Ramirez United States	11	1.8k 1.2×	1.5k 1.3×	383 0.6×	231 0.8×	232 1.3×	13	1.9k
Clare Brennan United States	13	1.3k 0.8×	1.0k 0.9×	346 0.6×	299 1.1×	179 1.0×	20	1.6k
Moti Ramgopal United States	21	1.1k 0.7×	901 0.8×	322 0.5×	418 1.5×	108 0.6×	83	1.5k
Anthony Mills United States	24	2.8k 1.8×	2.1k 1.8×	808 1.3×	497 1.8×	222 1.2×	63	3.1k

Countries citing papers authored by Erin Quirk

Since Specialization

Citations

This map shows the geographic impact of Erin Quirk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erin Quirk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erin Quirk more than expected).

Fields of papers citing papers by Erin Quirk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erin Quirk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erin Quirk. The network helps show where Erin Quirk may publish in the future.

Co-authorship network of co-authors of Erin Quirk

This figure shows the co-authorship network connecting the top 25 collaborators of Erin Quirk. A scholar is included among the top collaborators of Erin Quirk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erin Quirk. Erin Quirk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Noureddin, Mazen, Naim Alkhouri, Eric Lawitz, et al.. (2025). TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial. Nature Medicine. 31(7). 2297–2305. 2 indexed citations

Daar, Eric S., Edwin DeJesus, Peter Ruane, et al.. (2018). Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. The Lancet HIV. 5(7). e347–e356. 117 indexed citations

White, Kirsten, Will Garner, Joseph J. Eron, et al.. (2018). Repeat testing of low-level HIV-1 RNA. AIDS. 32(8). 1053–1057. 1 indexed citations

Wohl, David A., Amanda Clarke, Franco Maggiolo, et al.. (2018). Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine. Patient. 11(5). 561–573. 41 indexed citations

Molina, Jean‐Michel, Douglas Ward, Indira Brar, et al.. (2018). Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. The Lancet HIV. 5(7). e357–e365. 138 indexed citations

DeJesus, Edwin, Moti Ramgopal, Gordon Crofoot, et al.. (2017). Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. The Lancet HIV. 4(5). e205–e213. 37 indexed citations

Sax, Paul E., Anton Pozniak, Marisa Montes, et al.. (2017). Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. The Lancet. 390(10107). 2073–2082. 278 indexed citations breakdown →

Gallant, Joel E., Adriano Lazzarin, Anthony Mills, et al.. (2017). Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. The Lancet. 390(10107). 2063–2072. 257 indexed citations breakdown →

Zhang, Heather, Joseph M. Custodio, Xuelian Wei, et al.. (2017). P176 Clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir. Sexually Transmitted Infections. 93(Suppl 1). A74.2–A74. 10 indexed citations

10.

Sax, Paul E., Edwin DeJesus, Gordon Crofoot, et al.. (2017). Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. The Lancet HIV. 4(4). e154–e160. 72 indexed citations

11.

Gaur, Aditya H., Natella Rakhmanina, Mohammed Rassool, et al.. (2016). Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. The Lancet HIV. 3(12). e561–e568. 32 indexed citations

12.

Negra, Marinella Della, Marcos Tadeu Nolasco da Silva, Kristen Andreatta, et al.. (2015). Long-term Efficacy and Safety of Tenofovir Disoproxil Fumarate in HIV-1-infected Adolescents Failing Antiretroviral Therapy. The Pediatric Infectious Disease Journal. 34(4). 398–405. 14 indexed citations

13.

Gaur, Aditya H., Wasana Prasitsuebsai, Natella Rakhmanina, et al.. (2015). P026: Week 24 data from a phase 3 clinical trial of E/C/F/TAF in HIV-positive adolescents. Journal of the International AIDS Society. 18(3 (Suppl 2)). 11 indexed citations

14.

Lawitz, Eric, Mark Sulkowski, Ira M. Jacobson, et al.. (2013). Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics. Antiviral Research. 99(3). 214–220. 26 indexed citations

15.

Sax, Paul E., Edwin DeJesus, Anthony Mills, et al.. (2012). Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. The Lancet. 379(9835). 2439–2448. 335 indexed citations

16.

Nicholson, Ouzama, James G. Kublin, Xiao Sun, et al.. (2010). Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults. AIDS Research and Human Retroviruses. 27(5). 557–567. 16 indexed citations

17.

Asmuth, David M., Elizabeth Brown, Mark J. DiNubile, et al.. (2009). Comparative Cell‐Mediated Immunogenicity of DNA/DNA, DNA/Adenovirus Type 5 (Ad5), or Ad5/Ad5 HIV‐1 Clade BgagVaccine Prime‐Boost Regimens. The Journal of Infectious Diseases. 201(1). 132–141. 38 indexed citations

18.

Quirk, Erin, Robin Mogg, Deborah D. Brown, et al.. (2008). HIV Seroconversion without Infection after Receipt of Adenovirus‐Vectored HIV Type 1 Vaccine. Clinical Infectious Diseases. 47(12). 1593–1599. 15 indexed citations

19.

Chaparro, Juan D., Dominic N. Reeds, Weidong Wen, et al.. (2005). Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy. Metabolism. 54(5). 561–567. 28 indexed citations

20.

Quirk, Erin, Howard L. McLeod, & William G. Powderly. (2004). The Pharmacogenetics of Antiretroviral Therapy: A Review of Studies to Date. Clinical Infectious Diseases. 39(1). 98–106. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact